Millennium Management Llc Buys 9,533 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc purchased 9,533 shares of the company’s stock in a transaction dated Monday, March 30th. The stock was bought at an average cost of $25.86 per share, for a total transaction of $246,523.38. Following the completion of the purchase, the insider directly owned 145,678 shares of the company’s stock, valued at $3,767,233.08. The trade was a 7.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total transaction of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total transaction of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total transaction of $23,629.68.
• On Friday, March 27th, Millennium Management Llc purchased 15,321 shares of Sensei Biotherapeutics stock. The stock was bought at an average cost of $26.61 per share, for a total transaction of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc purchased 5,731 shares of Sensei Biotherapeutics stock. The stock was bought at an average cost of $28.62 per share, for a total transaction of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $25.49, for a total transaction of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $31.65, for a total transaction of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc bought 6,175 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $34.49 per share, for a total transaction of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc bought 6,005 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $28.16 per share, for a total transaction of $169,100.80.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $32.12, for a total transaction of $246,231.92.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock opened at $20.43 on Friday. The company has a market capitalization of $27.38 million, a price-to-earnings ratio of -0.14 and a beta of -0.18. Sensei Biotherapeutics, Inc. has a one year low of $5.25 and a one year high of $36.76. The company’s fifty day moving average price is $28.89 and its two-hundred day moving average price is $17.87.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing the consensus estimate of ($0.62) by ($130.83). As a group, sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

SNSE has been the topic of several analyst reports. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Finally, Leerink Partners initiated coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $40.00.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 32,041 shares of the company’s stock after purchasing an additional 20,525 shares during the quarter. Renaissance Technologies LLC owned about 2.39% of Sensei Biotherapeutics worth $1,010,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Key Headlines Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.